Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q3 2025 value amounting to $7.5 million.

  • Ironwood Pharmaceuticals' Other Accumulated Expenses fell 409.21% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 409.21%. This contributed to the annual value of $4.4 million for FY2024, which is 2870.74% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Other Accumulated Expenses is $7.5 million, which was down 409.21% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Other Accumulated Expenses ranged from a high of $14.3 million in Q3 2023 and a low of $1.9 million during Q1 2021
  • Over the past 5 years, Ironwood Pharmaceuticals' median Other Accumulated Expenses value was $5.2 million (recorded in 2025), while the average stood at $6.1 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Other Accumulated Expenses plummeted by 5511.46% in 2021, and later surged by 25592.33% in 2023.
  • Ironwood Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $3.4 million in 2021, then grew by 4.59% to $3.6 million in 2022, then surged by 72.14% to $6.2 million in 2023, then decreased by 28.71% to $4.4 million in 2024, then skyrocketed by 69.76% to $7.5 million in 2025.
  • Its Other Accumulated Expenses stands at $7.5 million for Q3 2025, versus $5.2 million for Q2 2025 and $7.5 million for Q1 2025.